MedTrace Logo

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

NCT01473251 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-12-17

No results posted yet for this study

Summary

The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.

Conditions

Interventions

DRUG

Avastin

1.25 mg monthly for 4 months

DRUG

Avastin

1.25 mg monthly for 4 months

DRUG

Lucentis

0.5 mg monthly for 4 months

Sponsors & Collaborators

  • Van Andel Research Institute

    collaborator OTHER

  • Vitreo-Retinal Associates, Michigan

    lead OTHER

Principal Investigators

  • Louis C. Glazer, MD · Vitreo Retinal Associates

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01473251 on ClinicalTrials.gov